News
Multinational consortium led by Julie Lessard awarded major grant
Published on December 9, 2024
As part of TRANSCAN-3’s joint transnational call 2023 for translational research on cancer epigenetics, Julie Lessard has been awarded a $2,03M grant for the multinational consortium she leads, alongside 5 colleagues from France, Spain and Israel.
The project supported by this consortium aims to identify the epigenetic remodeling events in hematopoietic cells and stromal cells of the bone marrow microenvironment, which promote the transformation of pre-leukemic B cell clones into leukemia. In addition, it will examine the extent to which different environmental exposures (notably to pathogens, pollutants or radiation) contribute to this tumor transformation. By identifying key biomarkers and epigenetic signatures, the project aims to develop innovative strategies for early detection and targeted intervention, in order to prevent the emergence of aggressive leukemias and improve survival rates in children.
The aim of TRANSCAN-3 is to promote research into the detection, diagnosis, prognosis and treatment of cancer, using innovative methods based on cancer epigenetics. In total, 13 research teams are benefiting from the financial support of 24 partners from 19 countries, including CIHR, through three consortia comprising Canadian researchers.
For full details of the call for projects, the funding consortia and the funding obtained, consult the official announcement.
